IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
28.13
-0.19 (-0.67%)
May 11, 2026, 4:00 PM EDT - Market closed
IDEAYA Biosciences Stock Forecast
Stock Price Forecast
The 14 analysts that cover IDEAYA Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $53.14, which forecasts a 88.91% increase in the stock price over the next year. The lowest target is $35 and the highest is $79.
Price Target: $53.14 (+88.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IDEAYA Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Buy | 9 | 8 | 9 | 9 | 9 | 9 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $52 → $50 | Buy | Maintains | $52 → $50 | +77.75% | May 7, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $31 → $35 | Hold | Maintains | $31 → $35 | +24.42% | Apr 14, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $44 → $48 | Buy | Maintains | $44 → $48 | +70.64% | Apr 14, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $49 → $53 | Buy | Maintains | $49 → $53 | +88.41% | Apr 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $52 → $58 | Buy | Maintains | $52 → $58 | +106.19% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
42.55M
from 218.71M
Decreased by -80.54%
Revenue Next Year
129.98M
from 42.55M
Increased by 205.45%
EPS This Year
-4.07
from -1.28
EPS Next Year
-3.58
from -4.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 103.3M | 259.2M | ||||||
| Avg | 42.6M | 130.0M | ||||||
| Low | n/a | 53.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -52.8% | 509.0% | ||||||
| Avg | -80.5% | 205.4% | ||||||
| Low | - | 26.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.32 | -2.59 | ||||||
| Avg | -4.07 | -3.58 | ||||||
| Low | -4.75 | -4.47 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.